The efficacy of adenovirus-mediated gene therapy of ovarian cancer is enhanced by using the cytomegalovirus promoter

Anticancer Research

Volumn 18, Issue 2 A, 1998, Pages 719-725

  Tong, Xiaowen ^a   Engehausen, Dirk G ^a   Freund, Christian T F ^a   Agoulnik, Irina ^a   Guo, Zongsheng ^a   Oehler, Martin K ^a   Kim, Tae Eung ^a   Hasenburg, Annette ^a   Contant, Charles F ^a   Woo, Savio L C ^a   Kieback, Dirk G ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cell killing efficacy; CMV promoter; Gene therapy; Ovarian cancer; RSV promoter

Indexed keywords

TETRAZOLIUM; THYMIDINE KINASE;

ADENOVIRUS; ARTICLE; CANCER CELL CULTURE; CELL KILLING; CONTROLLED STUDY; CYTOMEGALOVIRUS; FEMALE; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; ROUS SARCOMA ONCOVIRUS;

ADENOVIRIDAE; CELL SURVIVAL; CYTOMEGALOVIRUS; FEMALE; GENE THERAPY; HUMANS; OVARIAN NEOPLASMS; PROMOTER REGIONS (GENETICS); THYMIDINE KINASE; TUMOR CELLS, CULTURED;

EID: 15444355388     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Tong XW, Block A, Chen SH, Woo SLC and Kieback DG: Adenovirus-mediated gene therapy of human epithelial ovarian cancer by transduction with the thymidine kinase gene and exposure to ganciclovir. Anticancer Res 16: 1611-1618, 1996.
2. Tong XW, Block A, Chen SH, Contant C, Agoulnik I, Blankenburg K, Kaufman RH, Woo SLC and Kieback DG: In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration. Gynecol Oncol 61: 175-179, 1996.
3. Tong XW, Agoulnik I, Blankenburg KP, Contant CF, Hasenburg A, Runnebaum IB, Stickeler E, Kaplan AL, Woo SLC and Kieback DG: Human epithelial ovarian cancer xenotransplants into nude mice can be cured by adenovirus-mediated thymidine kinase gene therapy. Anticancer Res 17(2A): 811-813, 1997.
4. Behbakht K, Benjamin I, Chiu HC, Eck, SL, Deerlin PG, Rubin SC and Boyd J: Adenovirus-mediated gene therapy of ovarian cancer in a mouse model. Am J Obstet Gynecol 175: 1260-1265, 1996.
5. Moolten FL and Wells JM: Curability of tumors bearing herpes simplex virus thymidine kinase gene. J Natl Cancer Inst 82: 297-300, 1990.
6. Moolten FL, Wells JM, Heyman RA and Evans RM: Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Human Gene Therapy 1: 125-134, 1990.
7. O'Malley BWJ, Chen SH, Schwartz MR and Woo SL: Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res 55: 1080-1085, 1995.
8. Freeman SM, Whartenby KA, Koeplin DS, Moolten FL, Abboud CN and Abraham GN: Tumor regression when a fraction of tumor mass contains the HSV-TK gene. J cell Biochem 16F: 47, 1992.
9. Wilson KM, Stambrook PJ, Bi WL, Pavelic ZP, Pavelic L and Gluckman JL: HSV-tk gene therapy in head and neck squamous cell carcinoma. Enhancement by the local and distant bystander effect. Archives of Otolaryngology - Head & Neck Surgery 122(7): 746-749, 1996.
10. Hoganson DK, Batra RK, Olsen JC and Boucher RC: Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. Cancer Res 56(6): 1315-1323, 1996.
11. Aoki Y, Tani K, Takahashi K, Fukushima M, Ozawa K and Asano S: Regulation of recombinant human granulocyte colony-stimulation factor production using herpes simplex virus 1 thymidine kinase gene. Biochem Biophys Res Commun 200(3): 1245-1251, 1994.
12. Seachrist L: Successful gene therapy has researchers looking for the bystander effect [news]. J Natl Cancer Inst 86(2): 82-83, 1994.
13. Bi WL, Parysek LM, Warnick R and Stambrook PJ: In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther 4(6): 725-731, 1993.
14. Serfling E, Jasin M and Schaffner W: Enhancers and eukaryotic gene transcription. Trends Genetics 1: 224-230, 1985.
15. McKnight S and Tjian R: Transcriptional selectivity of viral genes in mammalian cells. Cell 46: 795-805, 1986.
16. Guo ZH, Wang LHM, Eisensmith RC and Woo SLC: Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. Gene Therapy 3: 802-810, 1996.
17. Chen SH, Shine HD, Goodman JC, Grossman RG and Woo SLC: Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 91: 3054-3057, 1994.
18. Chen SH, Chen XH, Wang Y, Kosai K, Finegold MJ, Rich S and Woo SLC: Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 92: 2577-2581, 1995.
19. Denizot F and Lang R: Rapid colorimetric assay for cell growth and survival modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 89: 271-277. 1986.
20. Carmichael J, Degraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942, 1987.